
HIV-1: Antibodies with low viral escape identified
A promising option for the prevention and treatment of HIV-1 infections is the use of broadly neutralizing antibodies targeting the HIV-1 envelope protein. However, their clinical application may be limited if the virus develops resistance. With the participation of Ernst Jung career award 2018 winner Till Schoofs, a highly broad and potent antibody has now been discovered that targets the CD4 binding site of HIV-1[1].